Methyl aminolevulinate

Drug Profile

Methyl aminolevulinate

Alternative Names: 5-ALA methylester; 5-ALA-methylesther; Aminolevulinic acid methyl ester; MAL-PDT; Methyl 5 aminolevulinate; Methylaminolevulinate; Metvix; Metvix Natural Daylight Photodynamic Therapy - Galderma; Metvix NDL-PDT; Metvix PDT; Metvixia; P 1202; Visonac

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Norwegian Radium Hospital; PhotoCure
  • Developer Galderma; Healthcare Logistics; Photocure
  • Class Amino acids; Antineoplastics; Levulinic acids; Oxidants; Skin disorder therapies; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Actinic keratosis; Basal cell cancer; Squamous cell cancer
  • Phase II Acne
  • Discontinued Skin aging

Most Recent Events

  • 31 Jul 2017 Discontinued - Phase-II for Skin aging in United Kingdom (Topical)
  • 01 Mar 2017 Galderma completes a phase II trial for Actinic keratosis in Denmark (Topical) (NCT03006185)
  • 09 Apr 2015 The product is approved for Actinic keratosis and Basal cell cancer in Mexico and is in phase-II development for Acne in USA, Canadd and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top